ABVC BIOPHARMA, INC. (ABVC) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$1.15

From 52W high−64.74%

Volume199152.00

Market cap$30.92M

P/E (TTM)—

P/S (TTM)−38.8x

Div yield—

Key dataSep 18, 2026

Open

$1.15

From 52W high

−64.74%

Volume

199152.00

Market cap

$30.92M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−4.4x

P/E (TTM)

—

RSI (14)

62.5

MomentumView details →

1D Return

+0.87%

YTD Return

−46.01%

SummaryUpdated Jun 1, 2026

ABVC BioPharma, Inc. (NASDAQ:ABVC) is a clinical-stage biopharmaceutical company founded in 2004 and headquartered in Fremont, California. The company operates as a subsidiary of YuanGene Corporation and focuses on developing innovative drugs and medical devices to address unmet medical needs. ABVC has built a diverse pipeline of therapeutic candidates targeting various conditions including cancer, mental health disorders, and retinal diseases, with multiple compounds currently progressing through different phases of clinical trials.

Ask drillr about ABVC BIOPHARMA, INC. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−4.4x

EV/Sales

−43.4x

P/S (TTM)

−38.8x

P/B (TTM)

3.0x

ProfitabilityView details →

Gross Margin

100.00%

Net Margin

992.85%

EBITDA Margin

983.23%

ROE (TTM)

−76.82%

ROA (TTM)

−40.73%

Asset Turnover

−0.04x

GrowthView details →

Revenue YoY

—

EPS YoY

−52.96%

FCF YoY

−39.33%

Revenue CAGR 3Y

−100.00%

EPS CAGR 3Y

+7.14%

EBITDA YoY

—

MomentumView details →

1D Return

+0.87%

YTD Return

−46.01%

1Y Return

−59.51%

RSI (14)

62.5

vs 50D SMA

+11.98%

vs 200D SMA

−20.06%

Capital & dividendView details →

Debt/Equity

0.17x

Current Ratio

0.07x

Quick Ratio

0.07x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.03

EPS Surprise

92.50%

Beats (12Q)

2/12

Next Q EPS Est

−$0.40

Avg Surprise (4Q)

1.04%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

−795950.00

Net Income (TTM)

−7.90M

Op. CF (TTM)

−2.69M

Next earningsNov 16, 2026 →

Latest newsMore news →

ABVC BioPharma, Inc. completed the spin-off of its subsidiary BioKey (Cayman), Inc. by distributing approximately 15% of BioKey's ordinary shares to ABVC stockholders as a pro rata dividend, effective August 21, 2026.25d ago

Similar companies

Sangamo Therapeutics, Inc.SGMO Barinthus Biotherapeutics plcBRNS OmniAb, Inc.OABIW BeyondSpring Inc.BYSI Quince Therapeutics, Inc.QNCX Leap Therapeutics, Inc.LPTX Find similar companies →

Latest newsMore news →